This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Estes, K. E. Articles by Penzak, S. R. Search for Related Content Social Bookmarking                         What's this?

Pharmacogenetic Considerations in the Management of HIV Infection

National Institutes of Health, Clinical Center, Pharmacy, Bethesda, Maryland

Kristin H. Busse, PharmD

National Institutes of Health, Clinical Center, Pharmacy, Bethesda, Maryland

Scott R. Penzak, PharmD

Clinical Pharmacokinetics Research Laboratory, National Institutes of Health, Clinical Center Pharmacy Department, Bethesda, Maryland, spenzak{at}mail.cc.nih.gov

Potent combination antiretroviral drug therapy has now been available to HIV-infected patients for more than a decade, resulting in a significant decline in disease-related morbidity and mortality. Nonetheless, a number of HIV-infected individuals fail to experience the full benefit of their antiretroviral medications; some lack a robust virologic response, while others experience treatment-limiting toxicities. A number of factors may contribute to variable drug response in patients with HIV infection. Virologic, immunologic, pharmacologic, and pharmacokinetic differences between HIV-infected patients have all been noted to contribute to interpatient variability in drug response. Recent data suggest that pharmacogenetic differences among HIV-infected individuals may also be an important variable that contributes to antiretroviral drug response. Pharmacogenetic studies of antiretroviral drug therapy have explored the influence of single nucleotide polymorphisms in genes responsible for key proteins involved in antiretroviral drug metabolism (cytochrome P50 enzymes) and drug transport (P-glycoprotein). In addition, the human leukocyte antigen genotype (HLA-B*57) has been found to predict abacavir-associated hypersensitivity reactions. Antiretroviral pharmacogenetics offers the possibility of optimizing virologic response and minimizing drug toxicity by individualizing anti-HIV pharmacotherapy. The authors review those genetic polymorphisms that have been shown, or are strongly suspected, to influence antiretroviral drug metabolism, transport, and toxicity.

Key Words: HIV • pharmacogenetics • pharmacogenomics • cytochrome P450 • P-glycoprotein.

Journal of Pharmacy Practice, Vol. 20, No. 3, 234-245 (2007)
DOI: 10.1177/0897190007304819


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?